Literature DB >> 2124138

Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer.

P Whitford1, E A Mallon, W D George, A M Campbell.   

Abstract

In 31 patients with carcinoma of the breast the phenotype and activation status of tumour infiltrating lymphocytes (TILs) was analysed by flow cytometry. The predominant cells, in all patients, were T lymphocytes and in the majority of cases CD8+ (cytotoxic/suppressor) T lymphocytes were present in greater numbers than CD4+ (helper) T lymphocytes. There was no relationship between the degree of lymphocytic infiltration and either tumour stage or grade but there appeared to be an inverse correlation with the levels of oestrogen receptor (ER) in the tumour (P less than 0.01). Both populations of T cells had significantly higher numbers of cells carrying HLA DR (class II major histocompatibility antigen) than the equivalent populations in peripheral blood from the same patient group (P less than 0.001). The transferrin receptor was found on similar numbers of CD8+ T cells in peripheral blood and among the tumour infiltrating lymphocytes while more of the CD4+ T cells infiltrating the tumour were found to carry this receptor (P = 0.034). The Tac (CD 25) antigen was also on similar numbers of CD8+ T cells from both peripheral blood and the tumour but was on fewer of the CD4+ T cells in the tumour with respect to peripheral blood (P = 0.029). In both TILs and blood lymphocytes, the Tac antigen was consistently present on greater numbers of CD4+ T lymphocytes than on the CD8+ T lymphocytes (P less than 0.001) and as this is a component of the interleukin 2 (IL-2) receptor this may be of relevance to the use of IL-2 in TIL cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124138      PMCID: PMC1971553          DOI: 10.1038/bjc.1990.419

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer.

Authors:  R Bilik; C Mor; B Hazaz; C Moroz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Antigenic phenotype of the lymphocytic component of medullary carcinoma of the breast.

Authors:  J Ben-Ezra; K Sheibani
Journal:  Cancer       Date:  1987-06-15       Impact factor: 6.860

4.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer.

Authors:  A K Bhan; C L DesMarais
Journal:  J Natl Cancer Inst       Date:  1983-09       Impact factor: 13.506

6.  Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions.

Authors:  S von Kleist; J Berling; W Bohle; C Wittekind
Journal:  Int J Cancer       Date:  1987-07-15       Impact factor: 7.396

7.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

Review 8.  Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies.

Authors:  P A Edwards
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

9.  Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity.

Authors:  O Eremin; R R Coombs; J Ashby
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

10.  Specific and non-specific lymphocyte cytotoxicity in colon carcinoma.

Authors:  B M Vose; P Gallagher; M Moore; P F Schofield
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

View more
  22 in total

1.  Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Authors:  H R Rosen; C Moroz; A Reiner; M Reinerova; M Stierer; J Svec; M Schemper; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

3.  Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.

Authors:  Peter Simsa; Jean-Luc Teillaud; David I Stott; József Tóth; Beatrix Kotlan
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

4.  Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes.

Authors:  Max O Meneveau; Zeyad T Sahli; Kevin T Lynch; Ileana S Mauldin; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

5.  Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.

Authors:  Mobolaji O Olurinde; Ching-Hung Shen; Adam Drake; Ailin Bai; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

6.  Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.

Authors:  Tanmoy Mondal; Gururaj N Shivange; Rachisan Gt Tihagam; Evan Lyerly; Michael Battista; Divpriya Talwar; Roxanna Mosavian; Karol Urbanek; Narmeen S Rashid; J Chuck Harrell; Paula D Bos; Edward B Stelow; M Sharon Stack; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal:  EMBO Mol Med       Date:  2021-02-15       Impact factor: 12.137

7.  Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.

Authors:  B Melichar; M A Nash; R Lenzi; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

8.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

9.  Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes.

Authors:  C J Punt; J A Barbuto; H Zhang; W J Grimes; K D Hatch; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

10.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.

Authors:  R Dadmarz; M K Sgagias; S A Rosenberg; D J Schwartzentruber
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.